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Restenosis after percutaneous transluminal coronary angioplasty
is caused by neointimal hyperplasia, which involves impairment of
nitric oxide (NO)-dependent pathways, and may be further exac-
erbated by a concomitant aging process. We compared the effects
of NO-releasing-aspirin (NCX-4016) and aspirin (ASA) on experi-
mental restenosis in both adult and elderly rats. Moreover, to
ascertain the efficacy of NCX-4016 during vascular aging, we fully
characterized the release of bioactive NO by the drug. Sprague–
Dawley rats aged 6 and 24 months were treated with NO releasing-
aspirin (55 mgkg) or ASA (30 mgkg) for 7 days before and 21 days
after standard carotid balloon injury. Histological examination and
immunohistochemical double-staining were used to evaluate re-
stenosis. Plasma nitrite and nitrate and S-nitrosothiols were de-
termined by a chemiluminescence-based assay. Electron spin res-
onance was used for determining nitrosylhemoglobin. Treatment
of aged rats with NCX-4016 was associated with increased bioac-
tive NO, compared with ASA. NO aspirin, but not ASA, reduced
experimental restenosis in old rats, an effect associated with
reduced vascular smooth muscle cell proliferation. NCX-4016, but
not ASA, was well tolerated and virtually devoid of gastric damage
in either adult or old rats. Thus, impairment of NO-dependent
mechanisms may be involved in the development of restenosis in
old rats. We suggest that an NCX-4016 derivative could be an
effective drug in reducing restenosis, especially in the presence of
aging andor gastrointestinal damage.
Aging can be defined as a progressive deterioration ofbiological functions after the organism has attained its
maximal reproductive competence, and is usually associated
with a decrease in cellular proliferative ability. However, with
aging, the diameter of arteries tends to increase, and thickening
of intima and medial layers is observed (1). This impairment may
be the result of a loss in replicative potential and telomere length
decrease (2–4). Moreover, in atherosclerosis and restenosis,
advancing age has been associated with a higher level of vascular
smooth muscle cell (VSMC) proliferation and neointimal lesion
formation. Indeed, VSMC proliferation after vascular injury is
greater in older rats and rabbits (5, 6). Cultured VSMCs from
older animals show higher percentage of their population in the
S phase (7). After de-endothelialization in vivo, no substantial
neointimal formation is observed in young rats, whereas the
intimal thickness markedly increases in the older rats (8). This
phenomenon could be related to a concurrent decrease in the
bioavailability of the antiproliferative effect of nitric oxide (NO).
Indeed, there is considerable growing experimental and clinical
evidence that aging is also associated with a decline in the release
of bioactive NO (9–13). Decreased free NO levels in aged rat
aortas are associated with increased formation of the toxic
peroxynitrite (14). Transient increased endothelial NO-synthase
activity could be a compensatory, but eventually futile, mecha-
nism to counter-regulate the age-related loss of NO (9–14).
Therefore, arteries from aged living organs are predisposed to
develop vascular lesions and have a reduced endogenous patho-
physiological cascade of events leading to vascular protection.
Treatment of myocardial infarction in older patients remains
problematic. Older patients have increased risk for adverse
events, a result of the presence of more comorbid conditions and
advanced multivessel coronary disease, and loss of ischemic
preconditioning (15–17). Primary percutaneous transluminal
coronary angioplasty (PTCA) does not seem to be more bene-
ficial in older than in adult patients, and the incremental adverse
effect of age does not vary by different treatment strategies (18).
Older patients had a higher mortality and morbidity despite
aspirin (ASA), beta-blockers, or thrombolytic therapy (19). A
highly clinically relevant pathophysiological process that involves
VSMC proliferation is restenosis. This complication is often
addressed by using ASA (as well as other antiplatelet drugs) (20,
21), which is limited by a modest therapeutic action and by its
common gastrointestinal adverse effects (22–25). Restenosis has
also been proposed to involve impaired NO production by the
damaged endothelium (26), and modulation of NO-dependent
pathways may be useful to modify the development of restenosis
(27–30). Thus, increased NO production at the site of balloon
injury may potentially exert beneficial effects (31). NO-
releasing-aspirin [2-acetoxybenzoic acid 3-(nitrooxymethyl)
phenyl ester (NCX-4016); ref. 32] exhibits little or no ulcerogenic
activity in several experimental models (23, 24, 32), inhibits
caspase activation (24), and has antithrombotic properties (33).
Because NCX-4016 could restore vascular NO deficiency with
increasing age and has been shown to reduce restenosis in
hypercholesterolemic mice (34), it could be also beneficial in the
restenotic process of aged rats.
Hence, to investigate the relevance of NO-dependent path-
ways after balloon injury in vascular aging, the present study was
designed to compare the effects of NCX-4016 and ASA on
experimental restenosis in both adult and elderly rats, the most
recognized experimental model of aging. Moreover, to ascertain
the therapeutic efficacy of NO-aspirin during vascular aging, we
fully characterized the release of bioactive NO.
Materials and Methods
Experimental Procedures. Studies were carried out according to
the guidelines of the American Heart Association for Accredi-
tation of Laboratory Animal Care. Experiments were carried out
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in adult (6 months old, 403  81 g of body weight) and elderly
(24 months old, 710  120 g of body weight) Sprague–Dawley
male rats. The animals were individually housed in stainless steel
cages under standard conditions (temperature 22  2°C; 50 
10% relative humidity; artificial light from 06.00 to 20.00). After
anesthesia with i.p. ketamine (80 mgkg of body weight) and
xylazine (5 mgkg of body weight), the carotid artery was
exposed (midline neck incision) under light microscope and
ligated distally (6–0 silk ties). Standard balloon injury was
induced by using a Fogarty 2F microcatheter into the common
carotid artery. Animals were treated with NCX-4016 (55 mgkg,
a generous gift from NicOx, Nice, France) or ASA (30 mgkg)
following the preventive protocol (i.e., drugs were administered
7 days before and 21 after balloon injury) (34). Additional
experiments were performed by using higher doses of NCX-4016
(up to 186 mgkg) or an NO donor (S-nitroso-N-acetylpenicil-
lamine, 500M). A control vehicle-treated (PEG 400) group was
also included.
Morphometric and Immunohistochemical Analysis. Rats were killed
with a lethal dose of sodium pentobarbital 21 days after injury,
and the stomach was excised. An observer unaware of the
treatments the rats had received examined each stomach and
measured the length (mm) of each hemorrhagic erosion. The
gastric damage score was calculated for each stomach by sum-
ming the lengths of all erosions (23, 24, 32, 33). Carotid arteries
were perfused with phosphate-buffered paraformaldehyde (4%,
0.1 molliter, pH 7.3) for histology or normal saline for immu-
nohistochemistry assessed by computer-assisted imaging analysis
(34–36). Carotid arteries were serially sectioned into 15–20 slices
(10 M) with a rotating diamond-coated knife, and sections
were stained with toluidine blue. The area confined by the
internal elastic lamina, the cross-sectional neointimal area, and
the percent area stenosis was measured by morphometry. Vessel
injury score was also determined (34). The number of prolifer-
ating VSMCs in the neointima was determined by immunohis-
tochemical double-staining of serial sections with -actin mono-
clonal mouse Ab (no. M0858, Dako) and proliferating cell
nuclear antigen (PCNA) Ab against PCNA (1:250 dilution; clone
PC10, Dako) (34, 37).
Ozone-Based Chemiluminescence Detection of Plasma Nitrite and
Nitrate (NOx), and S-nitrosothiols (RS-NO). NOx and RS-NO levels
were determined by a chemiluminescence-based assay (Sievers
Instruments 280, Boulder, CO) as described (38).
ESR Measurement of Nitrosylhemoglobin [HbFe(II)NO]. ESR spectra
were recorded at 100 K with a Bruker (Billerica, MA) EMX
spectrometer (X band) equipped with a high-sensitivity cylin-
drical cavity (ER4119HS) by using the following instrument
conditions (39): microwave frequency, 9.316 GHz; microwave
power, 20 mW; modulation frequency, 100 kHz; modulation
amplitude, 5 G (1 G  0.1 mT); number of scans, 20; resolution,
1,024 points; sweep time, 21 sec; and center field, 3,300 G with
a sweep width of 1,200 G. Spectra were analyzed by using
BRUKER SYSTEM (version 2.11) software. The concentration of
[HbFe(II)NO], expressed as M, was determined by double
integration of the signal, using CuSO4-EDTA in phosphate
buffer (50 mM, pH 7.4).
HPLC Analysis of Salicylic Acid in Blood. HPLC analyses were carried
out on an HP1050 with a Merck Licrospher (250  4 mm;
particle size, 5m) and a guard column (20 4 mm; particle size,
5 m). The HPLC pump operated at a flow rate of 1.0 ml min1
at 25 1°C. The mobile phase was CH3CNH2OH3PO4 10:99:1
(volvolvol) (solvent A) and CH3CN (solvent B); gradient
elution was used starting at 0% B, increasing linearly to 28% in
5 min, then to 33% at 12 min, 43% at 17 min, 60% at 20 min until
25 min. Volumes of 50 l were injected and the detector
(UV-visible diode array detector) was set at 228 nm.
Chemicals. Benzoic acid, ASA, PEG 400 (average molecular
weight 400), copper(II) sulfate, sodium fluoride, vanadium(III)
chloride, sodium nitrate, and EDTA were purchased from
Sigma–Aldrich.
Statistical Analysis. The gastric damage scores were compared by
using a one-way ANOVA followed by the Student–Newman–
Keul test. The inhibitory effects on VSMC proliferation and
restenosis induced by treatment with NCX-4016 and ASA were
compared by using the Kruskal–Wallis test. Regressions were
calculated by the least-squares method.
Results
Gastric Damage. Oral administration of ASA resulted in extensive
hemorrhagic damage in the stomach of the rats, but such damage
was not seen in rats given an equimolar dose of NCX-4016. The
mean gastric damage score in adult rats given ASA was 22  3,
whereas that in adult rats given NO-aspirin was 2  0.2 (P 
0.0001). In the old rats, ASA-treated rats had a mean gastric
damage score of 51  8, whereas that in the rats receiving
NO-aspirin was 3  0.8 (P  0.0001). Even when a much higher
dose of NCX-4016 (186 mgkg) was given to adult or old rats, the
mean gastric damage score remained very low (2.1  0.5 and
3.6 1.2, respectively, both P 0.0001 vs. ASA). These data are
consistent with several previous reports (23, 24, 31, 32) in which
NO-aspirin, unlike ASA, was not shown to induce significant
gastric damage.
Salicylate Levels. In Fig. 1 (Upper) are shown the representative
HPLC profiles of blood samples relative to vehicle-, ASA-, and
NO-aspirin-treated aged rats. Blood salicylate levels after oral
administration of ASA or equimolar doses of NO-aspirin did not
Fig. 1. (Upper) Representative HPLC profiles of blood from vehicle-, ASA- (30
mgkg), and NCX-4016-treated (55 mgkg) old rats. SA, salicylic acid. (Lower)
Plasma salicylates in ASA- and NCX-4016-treated old rats.
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differ significantly (P  not significant), indicating similar
salicylate release from the two drugs 4 h after last administration
(Fig. 1 Lower). These data were similar to those obtained from
adult rats (not shown).
Plasma NOx. We determined by chemiluminescence detection the
plasma levels of NOx. As shown in Fig. 2, the oral treatment of
old rats with NCX-4016 induced more than a 3-fold increase of
plasma NOx compared with the vehicle- (180  73 M vs.
54.14 3.13 M; P 0.0048) and ASA-treated groups (31.98
8.58 M; P 0.0019, t test). In addition, equimolar doses of ASA
were found to induce a significant decrease of plasma NOx
compared with vehicle-treated aged rats (P  0.0006). Plasma
NOx concentrations after drug administration (both ASA and
NCX-4016) were also similar to those obtained from adult rats
(not shown).
[HbFe(II)NO] in Blood. To further show the NO release by NO-
aspirin, we measured [HbFe(II)NO], a bioactive storage form of
NO formed by the reaction of NO addition to Fe(II)-Hb through
a coordinate bond (40), by ESR spectroscopy. [HbFe(II)NO] is
present in the blood as a pentacoordinate nitrosyl complex and
characterized by ESR spectroscopy as a three-line hyperfine
structure, because of the coupling of the unpaired electron in the
14N nucleus of NO (41). In Fig. 3 (Left) is shown a representative
ESR spectrum of blood from vehicle-treated aged rats charac-
terized by 2 main signals at g values 2.054 and 2.000, attributable
to copper-ceruloplasmin and to a semiquinone radical. As
reported (39), the 2 minor peaks at g  2.019 and g  2.009 are
relative to 2 of the 3 lines characteristic of the endogenous
[HbFe(II)NO] complex. The ESR spectra of blood samples from
NCX-4016-treated aged rats were characterized by a significant
increase of the 2 lines at g 2.019 and g 2.009, to demonstrate
an increase of [HbFe(II)NO] compared with the vehicle-treated
group. To better resolve and quantitate the [HbFe(II)NO]
signal, to each ESR spectrum was subtracted the spectrum from
vehicle-treated old rats. A representative ESR difference spec-
trum is shown in Fig. 3 (Left), which clearly shows the typical
three-line hyperfine structure of the pentacoordinate complex
[HbFe(II)NO] with coupling constants of Ax  Az  17 G at gx
 2.066 and gz  2.009. At g  1.986, the signal relative to the
hexacoordinated complex (R form) is also detectable. The
double integration of the difference signals gives an increase of
[HbFe(II)NO] content compared with the vehicle-treated group
of 1.65  0.62 nmolml. By contrast, the ESR spectra of blood
samples from ASA-treated old rats were practically superimpos-
able with those obtained from vehicle-treated animals (Fig. 3
Right). In particular, no differential increase of line intensity at
g  2.019 and g  2.009 was observed and no signal of
[HbFe(II)NO] (both in penta- and hexacoordinate state) was
detectable.
Plasma RS-NO Levels. In parallel to the increase of [HbFe(II)NO],
in NO-aspirin-treated old rats a significant rise (almost 3-fold)
in plasma levels of RS-NO was observed in respect to both
vehicle- (5.26  0.72 M vs. 1.78  0.76 M; P  0.0006) and
ASA-treated old rats (1.88  0.69 M; P  0.002) (Fig. 4).
Plasma RS-NO concentrations were similar to those obtained
Fig. 2. Plasma NOx levels in vehicle-, ASA- (30 mgkg), and NCX-4016-treated
(55 mgkg) old rats. Mean  SEM of 5 animals (3 replicates). **, P  0.0048
NCX-4016 vs. vehicle; ***, P  0.0006 ASA vs. vehicle.
Fig. 3. (Left) Representative ESR spectra of blood samples from vehicle- and
NCX-4016-treated (55 mgkg) old rats and the corresponding difference
spectrum (NCX-4016 after subtraction of vehicle). E, ceruloplasmin; F,
semiquinone radical. The 2 peaks at g  2.019 and g  2.009 (arrows) are
relative to [HbFe(II)NO]. (Right) Representative ESR spectra of blood from
vehicle- and ASA-treated (30 mgkg) old rats and the corresponding differ-
ence spectrum (ASA after subtraction of vehicle).
Fig. 4. Plasma RS-NO levels in vehicle-, ASA- (30 mgkg), and NCX-4016-
treated (55 mgkg) old rats; Mean SEM of 5 animals (3 replicates). ***, P
0.005 NCX-4016 vs. vehicle and ASA.
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from adult rats (not shown). This phenomenon was in accor-
dance with the transport of NO that, from erythrocyte HbFe(II),
is shuttled intramolecularly to the cysteine residue -93 and then
exported to plasma thiol-containing molecules, which readily
deliver NO in the presence of transition metals (42, 43).
Effects of NCX-4016 and ASA on Restenosis. In agreement with
previous studies (6, 8), the degree of restenosis after balloon
angioplasty was higher in older than younger adult rats (Fig. 5
and Table 1). The intimamedia ratio was 34 6% greater than
that of younger adult rats (P  0.01). Most important, the
balloon injury scores related to the treated groups were similar
among different protocols (Table 1).
Pretreatment with NO-aspirin for 7 days before and 21 days
after balloon injury significantly reduced the degree of restenosis
in adult and elderly rats (Table 1). Restenosis after balloon
dilation of carotid arteries is reflected as migration and prolif-
eration of VSMCs. Neointimal proliferation was reduced by
NCX-4016 but not ASA. Accordingly, the residual stenosis was
significantly reduced in animals treated with NCX-4016.
Double-label immunohistochemistry in serial carotid sections
for VSMCs indicated that the number of VSMCs was reduced by
NO-aspirin, but not ASA, at the lesion site (Table 1). These
beneficial effects clearly demonstrate the efficacy of NO-aspirin
on the development of restenosis in aged rats. Data obtained in
this experimental setting with a typical NO donor agent, S-
nitroso-N-acetylpenicillamine (500 M) (44), showed only a
13  4% reduction in proliferating VSMCs from old rats (n 
3, P  0.342 vs. untreated controls).
Discussion
The reduction of restenosis in adult rats elicited by NCX-4016,
but not ASA, was observed also in old rats. This phenomenon
was the result of reduced VSMC proliferation and cell density
indicating that this was likely caused by NO-mediated effects on
VSMCs. Moreover, administration of NO-aspirin did not cause
any gastric damage in either adult or old rats. The efficacy of
NCX-4016 in aged rats was studied first through an estimate of
plasma NOx content and then through the more specific mea-
surements of bioactive forms ([HbFe(II)NO] and RS-NO) of
NO. The rise in both of these markers unequivocally demon-
strate that, after the pretreatment period, NO-aspirin enhanced
the systemic and tissue release of bioactive NO in aged animals.
Importantly, the oral administration of equimolar doses of ASA
was found to reduce the endogenous production of NO, because
a significant decrease in plasma NOx levels was observed.
VSMC proliferation is involved in the pathogenesis of reste-
nosis after PTCA (45). NO inhibits VSMC growth in vitro and
experimental neointimal hyperplasia in vivo, indicating a role for
NO as a regulator of VSMC proliferation (10, 46–48). NO is also
involved in the control of other pathophysiological responses
including platelet function and inflammatory cells, vascular
reactivity, and endothelial permeability (10, 46–48). The ad-
ministration of L-arginine, the precursor to NO, reduces rest-
enotic lesion formation in cholesterol-fed rabbits (27, 28),
whereas L-NAME, a nonselective inhibitor of NO-synthase,
stimulates neointimal hyperplasia (29). Moreover, chronic inha-
lation of NO may reduce neointimal thickening in rats (30).
Thus, a large body of data indicates that NO-release or delivery
could be useful in restenosis after PTCA. Indeed, reduction of
neointimal proliferation observed in the present study seems to
agree very well with the potent inhibitory properties of NCX-
4016 on rat aortic SMC proliferation (49).
The therapeutic effects of NO-aspirin were obtained with a
1-week pretreatment prior to balloon injury following the same
protocol that reduced restenosis in hypercholesterolemic mice
(34). Although ASA-like drugs have little or no effect on
Fig. 5. Representative images of restenosis after balloon angioplasty and
neointimal hyperplasia in carotid artery. (A) Control vehicle-treated old rat.
(B) Vehicle-treated adult rat. Treatment with ASA (30 mgkg) in an old rat (C)
did not significantly reduce restenosis. In contrast, NCX-4016 (55 mgkg)
showed a significant reduction of neointimal hyperplasia and restenosis in an
old rat (D).
Table 1. Effects on restenosis of NCX-4016 vs. ASA in adult and old rats
Injury score Neointimal area, m2 % Lumen stenosis % Proliferating cells (VSMCPCNA)
Control adult rats (N  8; balloon injury  vehicle)
1.85  0.3 31.8  2.9 58.5  5.6 23.6  2.5
Control old rats (N  8; balloon injury  vehicle)
1.86  0.4 44.9  3.6* 78.9  6.8* 40.6  3.4*
Adult rats (N  8; balloon injury  55 mgkg of NCX-4016)
1.83  0.4 18.2  1.8†‡ 31.4  2.3†‡ 13.2  0.5†‡
Adult rats (N  8; balloon injury  30 mgkg of ASA)
1.84  0.5 29.6  2.5 53.1  4.3 22.1  2.1
Old rats (N  8; balloon injury  55 mgkg of NCX-4016)
1.85  0.4 24.1  1.6§¶ 37.2  2.8§¶ 15.1  0.9§¶
Old rats (N  8; balloon injury  30 mgkg of ASA)
1.86  0.5 41.8  4.5 73.2  5.9 38.3  3.5
Drugs or vehicle was administered 7 days before and 21 days after balloon injury. Data are expressed as the mean  SEM.
*, P  0.05 vs. vehicle-treated control adult rats.
†, P  0.01 vs. vehicle-treated control adult rats.
‡, P  0.05 vs. adult rats treated with ASA.
§, P  0.01 vs. vehicle-treated control old rats.
¶, P  0.05 vs. old rats treated with ASA.
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restenosis in humans (20, 21), NO-releasing drugs have not been
evaluated in human restenosis. Here, we showed that during
treatment with NO-releasing-aspirin, NO molecules released
from the drug enter into the physiological pathways involved in
the transport and targeted delivery of endogenous NO in
damaged arteries. The efficacy of NO-aspirin in reversing re-
stenosis may be also the result of additional NO-mediated effects
on vascular inflammation after PTCA. Our findings are in line
with several studies where NO has been shown to serve as
vasoprotector, including inhibition of platelet aggregation and
leukocyte adherence to the site of injury (47, 50). Further studies
at the molecular level are needed to better understand which are
the main signaling pathways involved in the protective action of
NCX-4016 and its long-term effects on vascular remodeling after
balloon injury. In the present study, using S-nitroso-N-
acetylpenicillamine, a typical NO donor, we observed a modest
reduction of restenosis in aged rats indicating that transient
administration of NO alone may be not sufficient to exert
protective effects in aged rats. To develop vascular protection, a
chronic intervention would be necessary to counterbalance NO
deficiency in arteries from aged animals. S-nitrosoglutathione,
an NO donor with preferential action on platelets, has been
shown to inhibit platelet aggregation after PTCA in patients
under ASA treatment without altering blood pressure (51).
However, routine clinical management using pure NO donors
could be difficult because of systemic effects on blood pressure.
The mechanisms underlying restenosis are further compli-
cated by vascular aging (5–14). Decreased vasorelaxation caused
by a decline in NO and endothelium-derived hyperpolarizing
factor, as well as increased vasoconstriction mediated by cyclo-
oxygenase products such as thromboxane A2, and concomitantly
increased sensitivity of apoptosis, are likely to occur in aging
(5–14, 52). More importantly, endothelium-dependent vasodi-
lation declines with aging in humans and the inhibitory effect of
NG-monomethyl-L-arginine (L-NMMA) on responses to acetyl-
choline decreases in parallel with advancing age, whereas vita-
min C increases vasodilation to acetylcholine in only the oldest
group (age  60 years) (53). Moreover, in older hypertensive
patients, vitamin C enhances endothelium-dependent vasodila-
tion and restores the inhibitory effect of L-NMMA on responses
to acetylcholine (53). Thus, in normotensive individuals, an
earlier primary dysfunction of the NO pathway and a later
production of oxidative stress cause age-related reduction in
endothelium-dependent vasodilation; these alterations are sim-
ilar but earlier in hypertensive patients compared with normo-
tensive subjects (53). Furthermore, enhanced oxidative stress
plays a critical role in the deleterious effect of aging on the
endothelium through acceleration of NO breakdown by reactive
oxygen species (8–14). Increased oxidative stress also occurs
during vascular response to PTCA (54, 55). Thus, increased lipid
peroxidation and oxidative stress with aging (56) together with
vascular changes related to NO bioavailability may contribute to
the higher severity of restenosis in elderly patients. In this regard,
NCX-4016 also exhibited antioxidant properties during myocar-
dial ischemia-reperfusion injury, in which a large amount of
oxygen radicals are formed during reperfusion (57). It was also
demonstrated that reduced expression of thymosin -10 may
contribute to senescence of vascular endothelium by reducing
endothelial cell plasticity (58). Moreover, there is an age-related
increase in c-fos activity that contributes to augmented cyclin A
expression and VSMC proliferation in old rabbits (59). These
signaling pathways can be also influenced by age-related NO
deficiency that was restored by NCX-4016 in plasma and tissue.
Thus, we show that NCX-4016, but not ASA, reduces reste-
nosis in aged rats. Although experimental laboratory animal
models may not entirely represent the complexity of the human
disease (60), from a clinical point of view, these results could be
extended to the common clinical conditions of both primary and
elective PTCA performed in elderly patients and in patients with
gastrointestinal restrictions to the use of ASA (as well as other
antiplatelet drugs) (22, 25). Indeed, the benefits of primary
PTCA are more impressive for the aging patient (61). The
survival gain and reduction in intracranial hemorrhage may
combine to magnify the advantages of performing PTCA on
aged patients. Emerging evidence concerning the aging popu-
lation validates continued examination of this invasive reperfu-
sion approach (61). Thus, the safety of NO-aspirin at the doses
tested may constitute a favorable pharmacological and clinical
safety profile in elderly patients in the presence of more comor-
bid conditions.
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